Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice.

Autor: Eliopoulos, N, Bovenzi, V, Le, N L O, Momparler, L F, Greenbaum, M, Létourneau, S, Cournoyer, D, Momparler, R L

Publikováno v: Gene Therapy. Nov98, Vol. 5 Issue 11, p1545. 7p.

Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells.

Autor: Dubuc C; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Savard M; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Bovenzi V; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Lessard A; Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland., Côté J; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Neugebauer W; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Geha S; Department of Pathology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada., Chemtob S; Department of Pediatrics, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, Québec, Canada., Gobeil F Jr; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada.

Publikováno v: Journal of cellular physiology [J Cell Physiol] 2019 Mar; Vol. 234 (3), pp. 2851-2865. Date of Electronic Publication: 2018 Aug 21.

DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.

Autor: Fan, Weina¹ (AUTHOR), Xing, Ying¹ (AUTHOR), Yan, Shi¹ (AUTHOR), Liu, Wei¹ (AUTHOR), Ning, Jinfeng² (AUTHOR), Tian, Fanglin¹ (AUTHOR), Wang, Xin¹ (AUTHOR), Zhan, Yuning¹ (AUTHOR), Luo, Lixin¹ (AUTHOR), Cao, Mengru¹ (AUTHOR) mengru527@hotmail.com, Huang, Jian¹ (AUTHOR) huangjian900103@163.com, Cai, Li¹ (AUTHOR) caili@ems.hrbmu.edu.cn

Publikováno v: Cancer Cell International. 6/13/2024, Vol. 24 Issue 1, p1-19. 19p.

Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer.

Autor: Dubuc C; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Savard M; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Bovenzi V; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Lessard A; Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, United States., Fortier A; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Côté J; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Neugebauer W; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada., Rizzolio F; Department of Biology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.; Dipartimento di Scienze Molecolari e Nanosistemi, Università Ca' Foscari Venezia, Mestre-Venezia, Italy., Geha S; Department of Pathology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada., Giordano A; Department of Biology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA., Chemtob S; Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montréal, Québec, Canada., Gobeil F; Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.; Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada.

Publikováno v: Oncotarget [Oncotarget] 2018 Jan 05; Vol. 9 (11), pp. 9885-9906. Date of Electronic Publication: 2018 Jan 05 (Print Publication: 2018).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.